Search global stocks & ETFs...Ctrl K
Learn Mode
ALMS
Stock Profile
08-11
Recommended Metric
Score Card
Explore Scores Tab
2.09
Bad
Valuation Score
Key Score
5.00
Very Good
Management
2.00
Bad
Growth
3.00
Average
Profitability
3.00
Average
Fin. Health
4.00
Good
Dividends
--
--
Analyst
4.00
Good
Insider Transactions
Explore Insider Tab ›Buy Transactions
Sell Transactions
Peers
Select stocks to comparePrice Targets & Ratings
View Analysis
1-year price targets, ending May 11, 2027
Current
$23.41
Baseline
High
$57.75
▲
146.69%
Avg
$40.19
▲
71.67%
Low
$25.25
▲
7.86%
Analyst Ratings based on 17 Analysts
Strong Buy
847%
Buy
741%
Hold
212%
Sell
000%
Strong Sell
000%
Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The company is headquartered in South San Francisco, California and currently employs 221 full-time employees. The company went IPO on 2024-06-28. The firm is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of ESK-001 for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and Parkinson’s Disease. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.Read More